-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Radezolid in Acne Vulgaris
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Radezolid in Acne Vulgaris report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Radezolid in Acne Vulgaris Drug Details: RX-1741 (radezolid) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Meropenem + Vaborbactam) in Bacterial Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Meropenem + Vaborbactam) in Bacterial Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Meropenem + Vaborbactam) in Bacterial Infections Drug Details: Meropenem and...
-
Product Insights
NewCommunity-Acquired Bacterial Pneumonia – Drugs In Development, 2024
Empower your strategies with our Community-Acquired Bacterial Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Community-acquired pneumonia is defined as pneumonia that is acquired outside the hospital. The most commonly identified pathogens are Streptococcus pneumoniae, Haemophilus influenzae, atypical bacteria (ie, Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella species), and viruses. Symptoms and signs are fever, cough, sputum production, pleuritic chest pain, dyspnea, tachypnea, and tachycardia The Community-Acquired Bacterial Pneumonia drugs in development market research report provide comprehensive information...
-
Product Insights
NewPyelonephritis – Drugs In Development, 2024
Empower your strategies with our Pyelonephritis – Drugs In Development, 2024 report and make more profitable business decisions. Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in the urethra or bladder and travels up into the kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion, and back or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract, and damage to nerves around the bladder. Treatment includes antibiotics....
-
Product Insights
NewSkin And Skin Structure Infections (SSSI) Caused By Bacteria – Drugs In Development, 2024
Empower your strategies with our Skin And Skin Structure Infections (SSSI) Caused By Bacteria – Drugs In Development, 2024 report and make more profitable business decisions. Skin and Skin Structure Infections (SSSIs) caused by bacteria encompass a spectrum of infections affecting the skin and underlying tissues, varying from mild to severe and instigated by diverse bacteria. Notable culprits include Staphylococcus aureus, including methicillin-resistant strains (MRSA), Streptococcus pyogenes (group A Streptococcus), and other streptococcal species. SSSI can manifest as cellulitis, erysipelas, impetigo,...
-
Product Insights
NewCommunity Acquired Pneumonia – Drugs In Development, 2024
Empower your strategies with our Community Acquired Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Community Acquired Pneumonia drugs in development market research...
-
Product Insights
NewBacterial Vaginosis – Drugs In Development, 2024
Empower your strategies with our Bacterial Vaginosis – Drugs In Development, 2024 report and make more profitable business decisions. Bacterial vaginosis (BV), also known as vaginal bacteriosis, is a type of vaginal inflammation caused by the overgrowth of bacteria present in the vagina. Symptoms include vaginal itching, burning during urination, and watery and thin vaginal discharge. Treatment includes antibiotics. The Bacterial Vaginosis drugs in development market research report provide comprehensive information on the therapeutics under development for Bacterial Vaginosis, complete with...
-
Product Insights
NewKlebsiella Infections – Drugs In Development, 2024
Empower your strategies with our Klebsiella Infections – Drugs In Development, 2024 report and make more profitable business decisions. Klebsiella infections are caused by bacteria of the genus Klebsiella, with K. pneumoniae being the most common species associated with human infections. These bacteria are part of the normal flora in the human digestive tract and respiratory system but can cause various infections, especially in individuals with weakened immune systems or underlying health conditions. Klebsiella infections can manifest in different parts of...
-
Product Insights
NewEscherichia coli Infections – Drugs In Development, 2024
Empower your strategies with our Escherichia coli Infections – Drugs In Development, 2024 report and make more profitable business decisions. Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. E. coli infections are caused by coming into contact with the feces of humans or animals, or eating or drinking contaminated food or beverage. Symptoms include diarrhea, which may range from mild and watery to severe and bloody; abdominal cramping; pain or tenderness; nausea; and vomiting....